8,605 results match your criteria Giant Cell Arteritis


[Hearing loss in giant cell arteritis: A case report].

Rev Med Interne 2022 Jun 22. Epub 2022 Jun 22.

Service de médecine interne et post-urgences, hôpital Pellegrin, CHU de Bordeaux, hôpital Pellegrin, place Amélie Raba Léon, 33000 Bordeaux, France; Université de Bordeaux, Talence, France. Electronic address:

Introduction: Hearing loss is a rare manifestation in giant cell arteritis. The different types of deafness are possible with a predominance of sensorineural deafness.

Case Report: We report a 75-year-old woman who presented with typical manifestations of giant cell arteritis associated concomitantly with the occurrence of bilateral mixed hearing loss confirmed on the audiogram. Read More

View Article and Full-Text PDF

Giant cell arteritis of the middle cerebral artery.

BMJ Case Rep 2022 Jun 24;15(6). Epub 2022 Jun 24.

Department of Rheumatology, Okayama City Hospital, Okayama, Japan.

View Article and Full-Text PDF

Immunosuppressive treatments selectively affect the humoral and cellular response to SARS-CoV-2 in vaccinated patients with vasculitis.

Rheumatology (Oxford) 2022 Jun 23. Epub 2022 Jun 23.

Department of Rheumatology, Fondazione IRCCS Policlinico San Matteo Pavia, University of Pavia, Pavia, Italy.

Objectives: To analyse humoral and cellular immune response to messenger RNA (mRNA) COVID-19 vaccines in patients with giant cell arteritis (GCA).

Methods: Consecutive patients with a diagnosis of GCA receiving two doses of BNT162b2 vaccine were assessed at baseline and three weeks from the second vaccine dose. Healthy subjects (n = 51) were included as controls (HC). Read More

View Article and Full-Text PDF

Novel PET Imaging of Inflammatory Targets and Cells for the Diagnosis and Monitoring of Giant Cell Arteritis and Polymyalgia Rheumatica.

Front Med (Lausanne) 2022 6;9:902155. Epub 2022 Jun 6.

Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands.

Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are two interrelated inflammatory diseases affecting patients above 50 years of age. Patients with GCA suffer from granulomatous inflammation of medium- to large-sized arteries. This inflammation can lead to severe ischemic complications (e. Read More

View Article and Full-Text PDF

Vision loss in giant cell arteritis: case-based review.

Rheumatol Int 2022 Jun 21. Epub 2022 Jun 21.

Department of Rheumatology, Patras University Hospital, University of Patras Medical School, Patras, Greece.

Prompt initiation of pulse glucocorticoid treatment is recommended in case of visual symptoms and suspected or proven giant cell arteritis (GCA). Pulse treatment in most cases prevents involvement of an initially unaffected fellow eye. We present the case of a biopsy-proven GCA in a 79-year-old man, complicated by sequential bilateral blindness. Read More

View Article and Full-Text PDF

Hypertrophic pachymeningitis in the context of the treatment of polymyalgia rheumatica.

BMJ Case Rep 2022 06 20;15(6). Epub 2022 Jun 20.

Department of Diagnostic and Generalist Medicine, Dokkyo Medical University, Shimotsuga-gun, Japan

View Article and Full-Text PDF

Comparing treatment options for large vessel vasculitis.

Expert Rev Clin Immunol 2022 Jun 17. Epub 2022 Jun 17.

Rheumatology Unit, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy.

Introduction: Giant cell arteritis (GCA) and Takayasu arteritis (TAK) are the major forms of large vessel vasculitis (LVV).Glucocorticoids represent the cornerstone of LVV treatment, however, relapses and recurrences frequently occur when they are tapered or stopped, determining a prolonged exposure to glucocorticoids and a subsequent increased risk of glucocorticoid-related side effects. Therefore, conventional and biologic immunosuppressive drugs have been proposed to obtain a glucocorticoid-sparing effect. Read More

View Article and Full-Text PDF

The Utility of the Bilateral Temporal Artery Biopsy for Diagnosis of Giant Cell Arteritis.

J Vasc Surg 2022 Jun 13. Epub 2022 Jun 13.

Heart and Vascular Center, Dartmouth-Hitchcock Medical Center, Lebanon, NH.

Objective: A surgical temporal artery biopsy (TAB) is the gold standard for diagnosis of giant cell arteritis (GCA). The necessity of performing a bilateral biopsy remains under debate. The primary objective of this study was to assess the rate of discordance between pathology results in patients who underwent bilateral temporal artery biopsy for suspected GCA. Read More

View Article and Full-Text PDF

Methylome and transcriptome profiling of giant cell arteritis monocytes reveals novel pathways involved in disease pathogenesis and molecular response to glucocorticoids.

Ann Rheum Dis 2022 Jun 15. Epub 2022 Jun 15.

Institute of Parasitology and Biomedicine López-Neyra (IPBLN), Spanish National Research Council (CSIC), Granada, Spain

Objectives: Giant cell arteritis (GCA) is a complex systemic vasculitis mediated by the interplay between both genetic and epigenetic factors. Monocytes are crucial players of the inflammation occurring in GCA. Therefore, characterisation of the monocyte methylome and transcriptome in GCA would be helpful to better understand disease pathogenesis. Read More

View Article and Full-Text PDF

Recent advances in the diagnosis and therapy of large vessel vasculitis.

Pol Arch Intern Med 2022 Jun 6. Epub 2022 Jun 6.

Large vessel vasculitis (LVV), including Takayasu arteritis (TAK) and giant cell arteritis (GCA), causes granulomatous vascular inflammation mainly in large vessels, and is the most common primary vasculitis in adults. Vascular inflammation may evoke many clinical features including vision impairment, stroke, limb ischemia, and aortic aneurysms. The best way to diagnose LVV is to combine medical history, physical examination, various laboratory tests, and imaging modalities. Read More

View Article and Full-Text PDF

Whole-Country and Regional Incidences of Giant Cell Arteritis in French Continental and Overseas Territories: A 7-Year Nationwide Database Analysis.

ACR Open Rheumatol 2022 Jun 13. Epub 2022 Jun 13.

Caen Universisty Hospital, Caen, France.

Objective: The incidence rate of giant cell arteritis (GCA) is poorly studied in France. Therefore, we conducted a national hospital database study to assess the overall and regional incidence rates of GCA in France, including overseas territories.

Methods: Through the national hospitalization database of all patients hospitalized in France, new incidental GCA was identified using International Classification of Diseases, 10th Revision medical codes (M31. Read More

View Article and Full-Text PDF

Comment on: Validation of the Southend giant cell arteritis probability score in a Scottish single-centre fast-track pathway.

Rheumatol Adv Pract 2022 19;6(2):rkac041. Epub 2022 May 19.

Department of Rheumatology and Clinical Immunology, Ziekenhuisgroep Twente (Hospital Group Twente), Almelo.

View Article and Full-Text PDF

Comment on: Validation of the Southend giant cell arteritis probability score in a Scottish single-centre fast-track pathway. Reply.

Rheumatol Adv Pract 2022 19;6(2):rkac042. Epub 2022 May 19.

Rheumatology Department, University Hospital Wishaw, NHS Lanarkshire, Wishaw, UK.

View Article and Full-Text PDF

High risk and low prevalence diseases: Giant cell arteritis.

Am J Emerg Med 2022 May 31;58:135-140. Epub 2022 May 31.

SAUSHEC, Department of Emergency Medicine, Brooke Army Medical Center, Fort Sam Houston, TX, USA. Electronic address:

Introduction: Giant cell arteritis (GCA) is a serious condition that carries with it a high rate of morbidity.

Objective: This review highlights the pearls and pitfalls of GCA in adult patients, including presentation, diagnosis, and management in the emergency department (ED) based on current evidence.

Discussion: GCA is an immune-mediated vasculitis of medium-sized vessels that primarily affects those over the age of 50 years. Read More

View Article and Full-Text PDF

Patients' Baseline Characteristics, but Not Tocilizumab Exposure, Affect Severe Outcomes Onset in Giant Cell Arteritis: A Real-World Study.

J Clin Med 2022 May 31;11(11). Epub 2022 May 31.

Internal Medicine Department, CHU Nîmes, University of Montpellier, 30029 Nîmes, France.

Objectives: Giant cell arteritis (GCA) is associated with severe outcomes such as infections and cardiovascular diseases. We describe here the impact of GCA patients' characteristics and treatment exposure on the occurrence of severe outcomes.

Methods: Data were collected retrospectively from real-world GCA patients with a minimum of six-months follow-up. Read More

View Article and Full-Text PDF

The Role of the Otolaryngologist in the Evaluation and Management of "Sinus Headache".

Otolaryngol Clin North Am 2022 Jun;55(3):501-518

Department of Otolaryngology/Head and Neck Surgery, Emory University School of Medicine, 550 Peachtree Street Northeast, Suite 1135, Atlanta, GA 30308, USA. Electronic address:

Patients will continue to present to the otolaryngologist's office with "sinus headaches" as their primary complaint. Otolaryngologists should take particular care in establishing a precise diagnosis. A thorough clinical history, comprehensive head and neck examination, well-performed nasal endoscopy, and imaging as necessary are essential components for effective diagnosis and treatment plan implementation. Read More

View Article and Full-Text PDF

Ocular Syphilis Mimicking Giant Cell Arteritis.

Cureus 2022 May 4;14(5):e24715. Epub 2022 May 4.

Internal Medicine and Nephrology, University of Oklahoma Health Sciences Center, Oklahoma City, USA.

Syphilis is a rare cause of vision loss that mostly occurs after an infection of the meninges, brain tissue, and parenchyma. Syphilis can mimic auto-immune disease like giant cell arteritis which also manifest as sudden vision loss. Spirochete can spread through sexual contact and cause painless ulcers. Read More

View Article and Full-Text PDF

FDG-PET/CT of Giant Cell Arteritis with Normal Inflammatory Markers.

Ann Neurol 2022 Jun 6. Epub 2022 Jun 6.

Department of Neurology, Kobe City Medical Center General Hospital, Kobe, Japan.

View Article and Full-Text PDF

Mass Switch From Intravenous to Subcutaneous Tocilizumab in Rheumatic Diseases During the SARS-COV-2 Pandemic.

J Clin Rheumatol 2022 Jun 3. Epub 2022 Jun 3.

From the Servicio de Reumatología, Hospital Universitario de Navarra.

Background: With the arrival of the SARS-CoV-2 pandemic in 2020, it was proposed to make the change from intravenous (IV) tocilizumab (TCZ) to its subcutaneous formulation, in order to avoid rheumatological patients having to go to the day hospital and guarantee enough IV TCZ for those critical patients with COVID who needed it. The aim of this study was to describe the rate and reasons for switching back to IV TCZ from subcutaneous TCZ.

Methods: We included patients from the rheumatology service that were on treatment with IV TCZ in February 2020 and were followed up until March 2021. Read More

View Article and Full-Text PDF

Large vessel vasculitis with rare presentation of acute rhabdomyolysis: A case report and review of literature.

World J Clin Cases 2022 May;10(13):4137-4144

Department of Nephrology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Traditional Chinese Medicine), Hangzhou 310006, Zhejiang Province, China.

Background: Musculoskeletal involvement in primary large vessel vasculitis (LVV), including giant cell arteritis and Takayasu's arteritis (TAK), tends to be subacute. With the progression of arterial disease, patients may develop polyarthralgia and myalgias, mainly involving muscle stiffness, limb/jaw claudication, cold/swelling extremities, Acute development of rhabdomyolysis in addition to aortic aneurysm is uncommon in LVV. Herein, we report a rare case of LVV with the first presentation of acute rhabdomyolysis. Read More

View Article and Full-Text PDF

Diagnostic use of ultrasound in giant cell arteritis in Counties Manukau District Health Board, New Zealand.

Rheumatol Adv Pract 2022 12;6(2):rkac040. Epub 2022 May 12.

Department of Rheumatology, Counties Manukau District Health Board, Middlemore Hospital, Auckland, New Zealand.

Objectives: A retrospective observational study was undertaken to assess the diagnostic performance (sensitivity and specificity) of colour duplex ultrasound (CDUS) compared with temporal artery biopsy (TAB) for the diagnosis of GCA in the Counties Manukau District Health Board (CMDHB), New Zealand using clinical diagnosis as the reference standard.

Methods: The study population included patients with clinically suspected GCA who were referred to Middlemore Hospital and underwent CDUS, TAB or both between January 2019 and December 2020.

Results: Sixty-nine patients were included in the study. Read More

View Article and Full-Text PDF

The Role of Ultrasound and FDG-PET/CT to Detect Extracranial Artery Involvement in Patients with Suspected Large Vessel Vasculitis.

Mod Rheumatol 2022 Jun 4. Epub 2022 Jun 4.

Department of Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain.

Objective: To assess the accuracy of ultrasound (US) versus FDG-PET/CT to identify extracranial involvement in suspected large vessel vasculitis (LVV) patients.

Methods: Retrospective observational study of patients referred to our US fast track clinic with suspected LVV. All patients underwent US exam within 24 hours per protocol. Read More

View Article and Full-Text PDF

Intravenous tocilizumab for the treatment of giant cell arteritis: a phase Ib dose-ranging pharmacokinetic bridging study.

Arthritis Res Ther 2022 Jun 4;24(1):133. Epub 2022 Jun 4.

Medical Center Monbijou, Bern, Switzerland.

Background: Subcutaneous tocilizumab (TCZ SC) is approved globally for giant cell arteritis (GCA). This phase Ib study investigated the pharmacokinetics, pharmacodynamics, safety, and exploratory efficacy of intravenous (IV) TCZ 6 and 7 mg/kg in patients with GCA. This study explored an IV dose resulting in a minimum exposure level within the range of effective trough concentrations achieved with TCZ SC dosing in GCA and not exceeding the exposure of the well-tolerated 8 mg/kg IV every 4 weeks (Q4W) in rheumatoid arthritis (RA). Read More

View Article and Full-Text PDF

Intestinal disease secondary to tocilizumab.

Rev Esp Enferm Dig 2022 Jun 3. Epub 2022 Jun 3.

Aparato Digestivo, Hospital Universitario La Paz.

It is presented a case study of intestinal affectation on a patient under tocilizumab treatment for giant cell arteritis. Read More

View Article and Full-Text PDF

[Giant cell arteritis diagnosed by a temporal artery biopsy without abnormal imaging and physical findings in an elderly patient presenting with fever].

Nihon Ronen Igakkai Zasshi 2022 ;59(2):233-236

Department of General Internal Medicine, Kobe City Medical Center General Hospital.

Giant cell arteritis (GCA) is considered in the differential diagnosis of fever of unknown origin in the elderly. We describe the case of an 83-year-old man with GCA diagnosed by temporal artery biopsy (TBA), who did not exhibit abnormal physical and imaging findings. The patient had fever and elevated C-reactive protein (CRP), which had persisted for two months. Read More

View Article and Full-Text PDF

A peculiar case of syphilis infection: The great imitator is on the rise.

IDCases 2022 18;28:e01521. Epub 2022 May 18.

Department of Internal Medicine, Groene Hart Ziekenhuis, Gouda, The Netherlands.

The incidence of syphilis is on the rise worldwide and can pose many diagnostic and therapeutic difficulties for doctors. Given the wide variety of presenting symptoms, syphilis is also known as the great imitator, which in turn frequently leads to a pronounced diagnostic- and therapeutic delay for patients. Here we present a case report of syphilitic uveitis and papillitis accompanied by acute vision loss, a rare presentation of a tertiary syphilis infection that clinically mimicked a giant cell arteritis (GCA) or arteritic anterior ischemic optic neuropathy (AAION). Read More

View Article and Full-Text PDF

Neurosyphilis mimicking giant cell arteritis both clinically and microscopically.

BMJ Case Rep 2022 May 31;15(5). Epub 2022 May 31.

Internal Medicine, Canisius Wilhelmina Hospital, Nijmegen, Gelderland, The Netherlands

Temporal arteritis is usually caused by giant cell arteritis (GCA). However, inflammation of the temporal artery can also occur secondary to autoimmune diseases or infections.We present a remarkable case of a man in his 70s with biopsy proven temporal arteritis, who was later diagnosed with meningovascular neurosyphilis. Read More

View Article and Full-Text PDF

Smoldering giant cell arteritis in a coronary artery.

Rheumatology (Oxford) 2022 May 28. Epub 2022 May 28.

Division of Rheumatology, Department of Medicine, Mayo Clinic, USA, Rochester, MN.

View Article and Full-Text PDF

The 100 Most-Cited Papers on Giant Cell Arteritis: A Bibliometric Analysis.

Curr Rheumatol Rev 2022 May 27. Epub 2022 May 27.

Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada.

Background: Giant cell arteritis (GCA) carries significant risk of vascular and visual morbidity. Given its clinical importance, the 100 most frequently cited articles on GCA were systematically identified and bibliometrically analyzed.

Methods: All databases belonging to the Web of Science platform were searched for research articles with no restriction on publication date. Read More

View Article and Full-Text PDF